With Final Data Unveiled, Vertex Will Move Its CF Combo Into Pivotal Trials In 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite controversies about incorrectly reported data and allegations of incomplete data, Vertex has demonstrated lung function benefit for a combination of Kalydeco and VX-809 in Phase II and will move the combination into Phase III trials early next year.